Stay updated on Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Expanded access status on the study page changed from Available (v3.5.3) to Temporarily not available (v3.5.4). This reflects that expanded access is not currently available outside the trial.
    Difference
    0.0%
    Check dated 2026-05-20T07:31:36.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The Taiwan location entry was updated from Taoyuan to Taoyuan City (Taiwan, 333). The postal code remains 333.
    Difference
    0.0%
    Check dated 2026-05-05T22:11:14.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    The release notes now show Revision: v3.5.3, replacing the prior v3.5.2. This indicates a newer version of the page, with no changes to the study details presented.
    Difference
    0.0%
    Check dated 2026-04-28T18:31:47.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    Updated the ClinicalTrials.gov page revision from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-21T16:17:11.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    The site revision was updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-23T22:36:37.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    Revision: v3.4.3 was added, replacing Revision: v3.4.2. This appears to be a minor UI/versioning update and does not affect the study information.
    Difference
    0.0%
    Check dated 2026-03-10T00:01:15.000Z thumbnail image

Stay in the know with updates to Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.